Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know

Corvus Pharmaceuticals, Inc. ( CRVS ) lead asset would have to be soquelitinib. It's an investigational oral small-molecule drug being developed by Corvus. It's been seen to selectively inhibit interleukin-2–inducibleI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation fo ...